Metastatic uveal melanoma (mUM) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Uveal melanoma (UM) is the most common primary intraocular cancer in adults, with over 8,000 new cases reported annually throughout the world. With a grim prognosis, up to 50% of patients with advanced UM develop metastatic disease, frequently via a hematogenous pathway in the liver. The most common type of intraocular cancer is uveal melanoma (UM), which arises from melanocytes in the iris, ciliary body, or choroid. Early diagnosis and local treatment are crucial because survival is correlated with the size of the primary tumor. Despite the inherent differences between these molecularly different conditions, dacarbazine, a chemotherapeutic option for treating cutaneous melanoma, has been used for uveal melanoma, but activity has been limited.

Description

Uveal melanoma (UM) is the most common primary intraocular cancer in adults, with over 8,000 new cases reported annually throughout the world. Patients with advanced UM have a grim prognosis because up to 50% of them develop metastatic disease, typically via a hematogenous pathway in the liver. Overall survival (OS) is limited once it becomes metastatic; it is frequently reported to be less than a year. Despite the fact that UM patients frequently have poor outcomes, there is currently no widely accepted global standard of management. Institutions frequently employ specific algorithms for rehabilitation based on their expertise and resources. The absence of approved, disease-specific treatments has made enrolling UM patients in clinical trials imperative. UM also continues to be misunderstood in comparison to other melanoma subtypes, particularly the more common cutaneous melanoma (CM). Understanding the biological and molecular differences between UM and CM is crucial to selecting the best management strategy and course of therapy.

Metastatic uveal melanoma (mUM)(Epidemiology)

Uveal melanoma, which arises from melanocytes in the iris, ciliary body, or choroid, is the most common type of intraocular cancer. Early diagnosis and local treatment are crucial because survival and primary tumor size are correlated. On the other hand, the typical patient only survives 6 to 12 months after being told they have metastatic disease. Primary intraocular malignancies are most likely to develop in adults with UM, who make up 3-5% of all melanomas. UM typically develops from choroidal melanocytes (85%-90%), but it can also come from the ciliary body (5-8%) and the iris (3-5%). The average age of diagnosis is around 62 years old, but the peak age of diagnosis is between 70 and 79 years old. Gender, race, and country all affect the incidence of UM. Males have a 30% higher incidence compared to females. Approximately five cases per million people are reported in the US, with non-Hispanic whites having a significantly higher incidence (6.02 cases per million) than Black people and Asians (0.31 and 0.39 cases per million, respectively). Hispanics have an average incidence of 1.67 cases per million people. Incidence increases with latitude in Europe, from 2 per million in Spain and Italy to 4 to 6 per million in Central Europe, and over 8 per million in Denmark and Norway. South Korea's incidence is comparable to that of Asian Americans at 0.42 cases per million.

Metastatic uveal melanoma (mUM)-Current Market Size & Forecast Trends

The market for metastatic uveal melanoma (mUM) is projected to grow from approximately USD 1 billion in 2024 to around USD 1.6 billion by 2035, reflecting a compound annual growth rate (CAGR) of 4.28% during this period. This growth is driven by the increasing incidence of uveal melanoma, advancements in treatment options such as immune checkpoint inhibitors and targeted therapies, and a rising awareness of the disease. The introduction of innovative therapies, including those targeting specific genetic mutations associated with uveal melanoma, is expected to enhance treatment outcomes and expand the market further. Additionally, the demand for precision medicine and personalized treatment approaches is likely to play a significant role in shaping the market landscape through 2035. Overall, the mUM market is well-positioned for substantial growth as new therapeutic strategies emerge and the healthcare infrastructure continues to improve.

Despite the inherent differences between these molecularly different conditions, dacarbazine, a chemotherapeutic option for treating cutaneous melanoma, has been used for uveal melanoma, but activity has been limited. Other chemotherapy regimens, including temozolomide, cisplatin, treosulfan, fotemustine, and various combinations, have been tested in uveal melanoma, but the outcomes have been disappointing so far. In the USA and Europe, the use of ipilimumab, a human monoclonal antibody that blocks CTLA-4, is permitted for the treatment of advanced, incurable melanoma. Despite response rates of 5 to 10% reported from evaluations in metastatic uveal melanoma, the median overall survival (OS) of 6 to 9 months in these trials suggests that only a small percentage of patients may experience delayed and durable responses. Nivolumab and pembrolizumab, fully human monoclonal antibodies that target the PD-1 receptor and are approved for the treatment of advanced melanoma in the USA and Europe. There is not yet enough information to determine how well PD-1 inhibition works in uveal melanoma. After preliminary analysis of pembrolizumab in seven patients with metastatic uveal melanoma who had progressed on ipilimumab revealed a median PFS of 3 months, a phase II trial (NCT02359851) is currently enrolling patients with this condition. Specially approved therapies and targeted management techniques are definitely needed to improve patient outcomes in this difficult disease. Due to the limited effectiveness of currently approved agents for treating advanced melanoma in treating metastatic uveal melanoma, clinical trials have been planned and are now being carried out.

Report Highlights

Metastatic uveal melanoma (mUM)- Current Market Trends

Metastatic uveal melanoma (mUM)- Current & Forecasted Cases across the G8 Countries

Metastatic uveal melanoma (mUM)- Market Opportunities and Sales Potential for Agents

Metastatic uveal melanoma (mUM)- Patient-based Market Forecast to 2035

Metastatic uveal melanoma (mUM)- Untapped Business Opportunities

Metastatic uveal melanoma (mUM)- Product Positioning Vis-a-vis Competitors' Products

Metastatic uveal melanoma (mUM)- KOLs Insight